首页 > 《癌症生物学与医学：英文版》 > 2017年4期 > The ascent of immune checkpoint inhibitors： is the understudy ready for a leading role？

The ascent of immune checkpoint inhibitors： is the understudy ready for a leading role？

在线阅读下载PDF 导出详情

摘要未填写

DOI 0dp9rznxj2/1801893

作者 Amy L. Cummings;Edward B. Garon

机构地区不详

出处《癌症生物学与医学：英文版》 2017年4期

关键词

分类 [医药卫生][肿瘤]

出版日期 2017年04月14日（中国期刊网平台首次上网日期，不代表论文的发表时间）

相关文献

1Zhang Rui,Cai Xiao-Ling,Liu Liu,Han Xue-Yao,Ji Li-Nong. Type 1 diabetes induced by immune checkpoint inhibitors.医药卫生,2020-11.
2Teresa Kim;Rodabe N. Amaria;Christine Spencer;Alexandre Reuben;Zachary A. Cooper;Jennifer A.Wargo. Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.肿瘤,2014-04.
3Yiqun Li,Yanfeng Wang,Ning Li,Xinjun Liang,Shu Zhang,Qingxia Fan,Xianli Yin,Zhixiang Zhuang,Yunpeng Liu,Jingdong Zhang,Xiaoge Kou,Haijun Zhong,Binghe Xu,Jing Huang. Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients.医药卫生,2022-12.
4Qian Fang-Fei,Han Bao-Hui. Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer.医药卫生,2020-11.
5Jennifer Kleponis;Richard Skelton;Lei Zheng. Fueling the engine and releasing the break： combinational therapy of cancer vaccines and immune checkpoint inhibitors.肿瘤,2015-03.
6Shi Wen-Jia,Zhao Wei. Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective.医药卫生,2020-11.
7Xu Jia-Li,Wang Xin-Zhu,Jiang Hu-Ning,Chen Yi,Wang Rong,Shu Yong-Qian. Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer.医药卫生,2020-11.
8Jiayi Deng,Ming Gao,Qing Gou,Chongrui Xu,Honghong Yan,Mingyi Yang,Jiakang Li,Xiaorong Yang,Xuewu Wei,Qing Zhou. Organ-specific efficacy in advanced non-small cell lung cancer patients treated with first-line single-agent immune checkpoint inhibitors.医药卫生,2022-12.
9Li Wen-Qian,Li Ling-Yu,Bai Ri-Lan,Qian Lei,Chen Nai-Fei,Cui Jiu-Wei. Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer.医药卫生,2020-11.
10Niki Karachaliou;Maria Gonzalez Cao;Cristina Teixidó;Santiago Viteri;Daniela Morales-Espinosa;Mariacarmela Santarpia;Rafael Rosell. Understanding the function and dysfunction of the immune system in lung cancer： the role of immune checkpoints.肿瘤,2015-02.

来源期刊

癌症生物学与医学：英文版

相关推荐

同分类资源更多

相关关键词

返回顶部